ROIV Stock Forecast & Price Target

Roivant Sciences is attractive because its pipeline is delivering de-risking clinical readouts while also expanding into commercialization, highlighted by VTAMA and brepocitinib’s approval for dermatomyositis. The most important fundamental driver is mosliciguat’s Phase II PHocus result, where placebo-adjusted PVR fell 56.3% at Week 16 with +35.2 meters in 6MWD and a 53.2% NT-proBNP reduction, all with cough below placebo and a once-daily profile in PH-ILD, a market with median survival of 1.5 to 2 years and under 20% penetration. Combined with a modeled ~$3B peak-sales opportunity in PH-ILD, an anticipated YE26 net cash position, and multiple shots on goal across IMVT-1402, brepocitinib, and other programs, the company has multiple potential growth pillars.

Roivant Sciences is facing a fundamentally weakened investment case because its pipeline has suffered repeated clinical failures, including IMVT assets in non-infectious uveitis and cutaneous sarcoidosis, as well as mosliciguat in PH-ILD. Additional concerns stem from unanticipated safety issues with batoclimab, IMVT-1402, brepocitinib, and other pipeline assets, which raise doubts about the quality and durability of the company’s development portfolio. The outlook is further pressured by litigation setbacks, unaudited financial statements, and other R&D, regulatory, and commercial setbacks that collectively undermine visibility into execution and future value creation.